MedTrace Logo

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

NCT00038883 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-11-07

No results posted yet for this study

Summary

High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.

Conditions

  • Leukemia, Lymphocytic, Chronic
  • Leukemia, Lymphocytic, Acute
  • Lymphoma, Low-Grade
  • Lymphoma, T-Cell
  • Lymphoma, B-Cell

Interventions

DRUG

Campath-1H

10 mg/day x 5, starting with the first day of chemotherapy

Sponsors & Collaborators

  • Leudosite

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Issa F. Khouri, MD, BS · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-09
Primary Completion
2006-05-31
Completion
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038883 on ClinicalTrials.gov